RE:RE:RE:Interesting
SPCEO1 wrote: What conclusions can we draw from this new addition? Have THTX seen something in the first patients that has led to the addition of this drug? Could it improve outcomes?
scarlet1967 wrote: "Melphalan flufenamide is indicated in combination with dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma, with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody."
Another PDC also uses the same combination.
Using steroids for cancer patients is common for many reasons some listed below. Melphalan flufenamide was approved not long ago also a PDC, they also use the steroid for better management of side effects mostly also to kill cancer cells.
It looks like only one Center is experimenting with the combination of TH1902 and the steroid. If no drug drug interactions it will make the treatment more tolerable/effective.
“Steroids have many indications for use in palliative care. Dexamethasone is the most commonly used corticosteroid due to the smaller number of tablets at higher doses, and the option for subcutaneous route if necessary. Steroids are substances that are naturally produced in the body.
“Steroids can also be made in a laboratory as drugs. They can be used in cancer treatment:
- to help destroy cancer cells and make chemotherapy more effective
- to reduce an allergic reaction to certain drugs
- as anti-sickness drugs
- to improve appetite
- to reduce symptoms such as pain caused by swelling (inflammation) around a cancer.
The most commonly used steroids are:
- hydrocortisone
- dexamethasone
- methylprednisolone
- prednisolone.”